Rapport Therapeutics Common Stock Statistics
Share Statistics
Rapport Therapeutics Common Stock has 36.58M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 36.58M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 24 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 2.11M, so 5.77% of the outstanding shares have been sold short.
| Short Interest | 2.11M |
| Short % of Shares Out | 5.77% |
| Short % of Float | 12.08% |
| Short Ratio (days to cover) | 20.11 |
Valuation Ratios
The PE ratio is -98.27 and the forward PE ratio is -7.37.
| PE Ratio | -98.27 |
| Forward PE | -7.37 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 24.25 |
| P/FCF Ratio | -118.63 |
| PEG Ratio | n/a |
Enterprise Valuation
Rapport Therapeutics Inc. Common Stock has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 17.14, with a Debt / Equity ratio of 0.
| Current Ratio | 17.14 |
| Quick Ratio | 17.14 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.25% and return on capital (ROIC) is -25.29%.
| Return on Equity (ROE) | -0.25% |
| Return on Assets (ROA) | -0.22% |
| Return on Capital (ROIC) | -25.29% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -599.76K |
| Employee Count | 58 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 10.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0, so Rapport Therapeutics Common Stock's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 23.15 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 36.39 |
| Average Volume (20 Days) | 151.45K |
Income Statement
In the last 12 months, Rapport Therapeutics Common Stock had revenue of $0 and earned -$34.79M in profits. Earnings per share was $-0.21.
| Revenue | 0 |
| Gross Profit | -112.00K |
| Operating Income | -36.18M |
| Net Income | -34.79M |
| EBITDA | -34.66M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.21 |
Balance Sheet
The company has $70.17M in cash and $2.15M in debt, giving a net cash position of $68.02M.
| Cash & Cash Equivalents | 70.17M |
| Total Debt | 2.15M |
| Net Cash | 68.02M |
| Retained Earnings | -45.44M |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was -$27.18M and capital expenditures -$1.64M, giving a free cash flow of -$28.82M.
| Operating Cash Flow | -27.18M |
| Capital Expenditures | -1.64M |
| Free Cash Flow | -28.82M |
| FCF Per Share | -0.18 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
RAPP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.11% |
| FCF Yield | -4.18% |
Analyst Forecast
The average price target for RAPP is $35, which is 85.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $35 |
| Price Target Difference | 85.8% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |